Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients

NCT01973842 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Subfertility

Interventions

DRUG: 0.1 mg triptorelin
DRUG: 0.2 mg triptorelin
DRUG: 0.4 mg triptorelin

Sponsor

Aristotle University Of Thessaloniki

Collaborators

[object Object]